About This Study
The purpose of this study is to learn more about a study drug called IDRX-42 (GSK6042981). We want to see if IDRX-42 works better than sunitinib, a medicine used to treat a type of cancer called gastrointestinal stromal tumor (GIST). This study is for people whose cancer has grown after treatment with imatinib or who had side effects that made it hard to take imatinib. Researchers will also learn more about the safety of IDRX-42 and how it affects people's symptoms and daily life. This information may help doctors find better treatments for people with GIST in the future. Volunteers must be adults with GIST that has spread to other parts of the body or cannot be removed with surgery. They must have received treatment with imatinib in the past. The study team will provide more information
What Activities Are a Part of this Study?
- Informed Consent Review
- Use of Study Treatments or Placebo
- Use of Study Health Plans
- After Study Follow-Up Activities
- Review of Medical History
- Physical Examinations
- Phone Calls and/or Emails
- Study Visits and Consultations
- Laboratory and Imaging Tests
- Specimen Sample Collection
Age & Gender
- 18 - 100+ years old
- Female
- Male
Language
- This study enrolls English and Spanish speakers
Additional Study Information
- Compensation Offered
- Reimbursement offered
Study Locations
- Greater Charlotte, NC